吉林大学学报(医学版)

• 基础研究 • 上一篇    下一篇

洛伐他汀对TNF-α诱导人脐静脉内皮细胞MCP-1和IL-10表达的影响

沈阳医学院沈洲医院血管外科,辽宁 沈阳110032   

  1. 沈阳医学院沈洲医院血管外科,辽宁 沈阳110032
  • 收稿日期:2013-05-14 出版日期:2013-09-28 发布日期:2013-12-13
  • 通讯作者: 赵铁柱(Tel:024-66607056, E-mail:sharonwang2008@vip.sina.com) E-mail:sharonwang2008@vip.sina.com
  • 作者简介:赵铁柱(1979-),男,辽宁省沈阳市人,主治医师,主要从事动脉硬化的病因及治疗的研究。
  • 基金资助:

    辽宁省教育厅科学技术研究项目资助课题 (2008848)

Influence of lovastatin in expressions of MCP-1 and IL-10 of HUVECs treated with TNF-α

HAO Tie-zhu,SHEN Huan,TAO Zhi-kan,WANG Wei,ZHAO Dan-dan   

  1. Department of Cardiovascular Surgery,Shenzhou Hospital,Shenyang Medical College,Shenyang 110032,China
  • Received:2013-05-14 Online:2013-09-28 Published:2013-12-13

摘要:

目的:观察洛伐他汀(LVT)对肿瘤坏死因子α(TNF-α)刺激人脐静脉内皮细胞(HUVECs)后单核细胞趋化蛋白-1 (MCP-1)和白细胞介素-10 (IL-10)表达的影响,探讨其抗动脉粥样硬化(AS)的可能机制。方法:体外常规培养HUVECs,分为对照组,用含10% FBS的RPMI 1640培养液培养;TNF-α处理组,用含10% FBS的RPMI 1640培养液+TNF-α (20 μg/L) 处理;应用活性氧检测试剂盒检测活性氧含量;LVT干预组,用含10% FBS的 RPMI 1640 培养液+TNF-α (20 μg/L)+LVT (10  μmol/L) 处理。实时定量RT-PCR方法检测各组细胞MCP-1和IL-10 mRNA的表达;Western blotting方法检测各组HUVECs内MCP-1、IL-10和NF-κB蛋白表达。结果:与对照组相比较,TNF-α处理组ROS含量明显增高 (P<0.05);与TNF-α处理组比较,LVT干预组ROS含量明显降低(P<0.05);与对照组比较,TNF-α处理组MCP-1和NF-κB mRNA及蛋白表达水平明显增高(P<0.05),而IL-10 mRNA和蛋白的表达水平明显降低(P<0.05);与TNF-α处理组比较,LVT干预组细胞MCP-1和NF-κB mRNA及蛋白表达水平明显降低(P<0.05),而IL-10 mRNA和蛋白表达水平明显增高(P<0.05)。结论:LVT抑制HUVECs中TNF-α诱导的MCP-1 mRNA和蛋白上调,增强IL-10蛋白表达。LVT可能通过NF-κB途径对抗炎症反应从而防止AS的形成。

关键词: 人脐静脉内皮细胞, 单核细胞趋化蛋白1, 白细胞介素10, 动脉粥样硬化, 洛伐他汀

Abstract:

Abstract:Objective To investigate the potential anti-atherosclerosis (AS) mechanism of lovastatin by  observing the influence of lovastatin on the  expressions of monocyte chemotactic protein-1 (MCP-1) and interleukin 10 (IL-10) in human umbilical vein endothelial cells (HUVECs) treated with tumor necrosis factor-α(TNF-α).Methods The HUVECs were routinely cultured in the medium RPMI 1640 containing 10% fetal bovine serum (FBS) in vitro and divided into 3 groups: control group,TNF-α  treated group (RPMI 1640 medium +TNF-α (20 μg/L),and lovastatin treated group (RPMI 1640 medium + 20 μg/L TNF-α+ 10 μmol/L Lovastatin);Application kit to detect ROS content; Real-time RT-PCR was used to measure the mRNA expressions of MCP-1 and IL-10 in HUVECs in each group;Western blotting method was used to analyze the protein expressions of MCP-1,NFκB and IL-10 in HUVECs in each group.Results Compared with the control group, the expressions of  ROS in TNF-α treated group were enhanced obviously(P<0.05).Compared with TNF-α treated group, the ROS expressions in the lovastatin treated group were decreased significantly(P<0.05).Compared  with  control group,the mRNA and protein expression levels  of MCP-1 and NFκB in TNF-α treated group were enhanced obviously (P<0.05),and the mRNA and protein expression levels  of IL-10 were decreased statistically (P<0.05).Compared with TNF-α treated group,the mRNA and protein expression levels  of MCP-1 and NFκB  in  lovastatin treated group were decreased significantly(P<0.05),but the expression level of IL-10 was increased statistically (P<0.05).Conclusion Lovastatin can inhibit the up-regulation of MCP-1 and NFκB and increase the expression of IL-10 in the HUVECs treated with TNF-α.Lavastatin may inhibit inflammation and prevent artherosclerosis through NF-κB pathway.

Key words: human umbilical vein endothelial cells, monocyte chemotactic protein-1, interleukin-10, atherosclerosis, lovastatin

中图分类号: 

  • R543